the staff of the Ridgewood blog
Ridgewood NJ, Eli Lilly, the pharmaceutical giant, launched a direct-to-consumer website yesterday, providing its customers with the option to obtain third-party prescriptions for its medications, including the newly approved weight loss injectable Zepbound (similar to Novo Nordisk’s Wegovy/Ozempic). Through the site, users can connect to a telehealth service, enabling them to quickly receive prescriptions before making a purchase.
